Thyroid Manager requires free registration
Login or Register

TKI Therapy of Aggressive Differentiated Thyroid Cancer

SPECIAL ENDOTEXT AND THYROIDMANAGER SYMPOSIUM

TYROSINE KINASE INHIBITORS IN MANAGEMENT OF AGGRESSIVE DIFFERENTIATED THYROID CANCER

CME Credits are available for Symposium readers--Click here--http://www.cvent.com/d/24q4qp

PLEASE  TAKE A SHORT EVALUATION SURVEY AFTER YOU VISIT/READ THIS SYMPOSIUM---CLICK HERE

 

INTRODUCTION   James Hennessey, MD   Harvard Medical School,  Boston, MA

 S1- CONTEMPORARY MANAGEMENT OF DIFFERENTIATED THYROID CANCER

Furio Pacini, MD Thyroid Unit, University of Siena, Siena Italy

Leslie J De Groot, MD, University of Rhode Island, Providence, RI

S2- DEFINING RAI REFRACTORY THYROID CANCER: WHEN IS RAI THERAPY UNLIKELY TO ACHIEVE A THERAPEUTIC RESPONSE?

R Michael Tuttle, MD  and  Mona M. Sabra, MD

Endocrinology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021

S3- SELECTION OF PATIENTS FOR TYROSINE KINASE INHIBITOR TREATMENT

Furio Pacini, MD Professor of Endocrinology, Director, Section of Endocrinology and Metabolism, University of Siena, Siena, Italy

Martin Schlumberger , MD Professor of Oncology, University of Paris-Sud, Director, Nuclear Medicine and Endocrine Tumors Division, Institut Gustave-Roussy, Villejuif, Paris, France.

S4- NEW TREATMENT ALGORITHMS FOR SYSTEMIC THERAPY WITH TKIs IN MANAGING AGGRESSIVE THYROID CANCER

Joshua Klopper  and  Bryan Haugen

University of Colorado School of Medicine

S5- CHANGING OUTLOOK ON MANAGEMENT OF AGGRESSIVE DIFFERENTIATED CANCER

James Fagin, MD

Organized and edited by James V Hennessey, MD and Leslie J De Groot, MD

 

AVAILABLE IN SOFT-COVER PRINT FORMAT    AT  AMAZON.COM, AND  AMAZON.CO.UK, (or DE, FR, IT, ES) (Title ID: 4816017) , AND www.createspace.com/4816017    List Price: $15.00
8 x10,  80 pages, ISBN-13: 978-1499618716

 This small book offers up to the minute information on a serious medical problem- management of differentiated thyroid cancer no longer amendable to surgery or RAI. It covers contemporary initial diagnosis and treatment, making an evidence based decision to move beyond RAI therapy, detailed and practical information on use of tyrosine kinase targeted treatment, and a look at what may come after single-agent TKIs. The authors are all steeped in management of thyroid cancer, including Furio Pacini and Leslie De Groot, Martin Schlumberger, Michael Tuttle and Monica Sabra, Joshua Klopper and Brian Haugen, James Fagin, and James Hennessey..